A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Must have received: anti-CD20 therapy — LBCL, MCL, FL

LBCL patients must have progressed after both anti-CD20 and at least one systemic chemotherapy regimen; MCL patients must have had anti-CD20; FL patients should have failed anti-CD20

Must have received: systemic chemotherapy — LBCL

LBCL patients must have progressed after both anti-CD20 and at least one systemic chemotherapy regimen

Must have received: CAR-T cell therapy — LBCL

LBCL patients must have considered or be ineligible for CAR-T, T cell engager, and stem cell transplant modalities

Must have received: T cell engager — LBCL

LBCL patients must have considered or be ineligible for CAR-T, T cell engager, and stem cell transplant modalities

Must have received: stem cell transplant — LBCL

LBCL patients must have considered or be ineligible for CAR-T, T cell engager, and stem cell transplant modalities

Must have received: Bruton's Tyrosine Kinase (BTK) inhibitor — MCL

MCL patients must have had anti-CD20 and Bruton's Tyrosine Kinase (BTK) inhibitor

Cannot have received: CAR-T cell therapy

Exception: within 90 days prior to Cycle 1 Day 1 (C1D1)

received Chimeric antigen receptor-T (CAR-T) or T cell engager therapies within 90 days prior to Cycle 1 Day 1 (C1D1)

Cannot have received: T cell engager

Exception: within 90 days prior to Cycle 1 Day 1 (C1D1)

received Chimeric antigen receptor-T (CAR-T) or T cell engager therapies within 90 days prior to Cycle 1 Day 1 (C1D1)

Cannot have received: investigational drug

Exception: within 21 days or 5 half-lives

any investigational drug or other systemic anticancer therapies (except low-dose corticosteroids) within 21 days or 5 half-lives

Cannot have received: systemic anticancer therapy

Exception: within 21 days or 5 half-lives

any investigational drug or other systemic anticancer therapies (except low-dose corticosteroids) within 21 days or 5 half-lives

Cannot have received: curative radiation

Exception: within 14 days

curative radiation within 14 days (localized palliative radiotherapy is allowed)

Cannot have received: allogeneic Hematopoietic stem cell transplantation

Exception: within 180 days (unless stable without active GVHD for ≥2 months)

allogeneic Hematopoietic stem cell transplantation (HSCT) within 180 days (unless stable without active (graft-versus-host disease) GVHD for ≥2 months)

Cannot have received: autologous Hematopoietic stem cell transplantation

Exception: within 90 days (unless resolved toxicities)

autologous HSCT within 90 days (unless resolved toxicities)